25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

VRPX (Virpax Pharmaceuticals Inc) Stock Analysis
Buy, Hold or Sell?

Let's analyze Virpax Pharmaceuticals Inc together

I guess you are interested in Virpax Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • ๐Ÿ“Š Fundamental Analysis (FA) โ€“ Virpax Pharmaceuticals Incโ€™s Financial Insights
  • ๐Ÿ“ˆ Technical Analysis (TA) โ€“ Virpax Pharmaceuticals Incโ€™s Price Targets

I'm going to help you getting a better view of Virpax Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Virpax Pharmaceuticals Inc

I send you an email if I find something interesting about Virpax Pharmaceuticals Inc.

1. Quick Overview

1.1. Quick analysis of Virpax Pharmaceuticals Inc (30 sec.)










1.2. What can you expect buying and holding a share of Virpax Pharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$-214.78
Expected worth in 1 year
$-1,080.13
How sure are you?
14.3%

+ What do you gain per year?

Total Gains per Share
$-865.35
Return On Investment
-7,795,914.9%

For what price can you sell your share?

Current Price per Share
$0.01
Expected price per share
$0.011 - $0.209
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Virpax Pharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)
$0.01
Intrinsic Value Per Share
$-57,948.98 - $-41,982.60
Total Value Per Share
$-58,163.76 - $-42,197.38

2.2. Growth of Virpax Pharmaceuticals Inc (5 min.)




Is Virpax Pharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?-$913.7m$1.9m-$915.6m-100.2%

How much money is Virpax Pharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money-$12b-$15.1m-$12b-99.9%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Virpax Pharmaceuticals Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Virpax Pharmaceuticals Inc?

Welcome investor! Virpax Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of Virpax Pharmaceuticals Inc.

First you should know what it really means to hold a share of Virpax Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of Virpax Pharmaceuticals Inc is $0.0111. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Virpax Pharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Virpax Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-214.78. Based on the TTM, the Book Value Change Per Share is $-216.34 per quarter. Based on the YOY, the Book Value Change Per Share is $-11.79 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Virpax Pharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-2,836.41-25,553,230.1%-2,836.41-25,553,230.1%-12.22-110,134.7%-955.30-8,606,312.8%-575.82-5,187,563.8%-411.76-3,709,515.0%
Usd Book Value Change Per Share-216.34-1,948,978.7%-216.34-1,948,978.7%-11.79-106,184.8%-81.65-735,581.5%-42.52-383,028.5%-30.68-276,421.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-216.34-1,948,978.7%-216.34-1,948,978.7%-11.79-106,184.8%-81.65-735,581.5%-42.52-383,028.5%-30.68-276,421.9%
Usd Price Per Share0.38-0.38-0.32-0.44-0.95-0.68-
Price to Earnings Ratio0.00-0.00--0.03--0.02--0.08--0.06-
Price-to-Total Gains Ratio0.00-0.00--0.03--0.02-0.01-0.01-
Price to Book Ratio0.00-0.00-0.21-0.08-0.07-0.05-
Price-to-Total Gains Ratio0.00-0.00--0.03--0.02-0.01-0.01-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.0111
Number of shares90090
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-216.34-42.52
Usd Total Gains Per Share-216.34-42.52
Gains per Quarter (90090 shares)-19,489,767.77-3,830,281.34
Gains per Year (90090 shares)-77,959,071.09-15,321,125.36
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-77959071-779590810-15321125-15321135
20-155918142-1559181520-30642251-30642260
30-233877213-2338772230-45963376-45963385
40-311836284-3118362940-61284501-61284510
50-389795355-3897953650-76605627-76605635
60-467754427-4677544360-91926752-91926760
70-545713498-5457135070-107247878-107247885
80-623672569-6236725780-122569003-122569010
90-701631640-7016316490-137890128-137890135
100-779590711-7795907200-153211254-153211260

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.07.00.00.0%0.07.00.00.0%
Book Value Change Per Share0.01.00.00.0%0.03.00.00.0%1.04.00.020.0%1.06.00.014.3%1.06.00.014.3%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.07.00.0%0.00.07.00.0%
Total Gains per Share0.01.00.00.0%0.03.00.00.0%1.04.00.020.0%1.06.00.014.3%1.06.00.014.3%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Virpax Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---216.337-216.3370%-11.787-95%-81.650-62%-42.516-80%-30.683-86%
Book Value Per Share---214.780-214.7800%1.557-13896%-66.627-69%-34.621-84%-25.078-88%
Current Ratio--0.6300.6300%1.251-50%2.746-77%5.443-88%3.897-84%
Debt To Asset Ratio--1.5871.5870%0.799+99%0.848+87%2.531-37%13.219-88%
Debt To Equity Ratio----0%3.978-100%1.388-100%0.844-100%0.603-100%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value---954700326.860-954700326.8600%1845088.000-51843%-312060569.953-67%-224291408.465-77%-224291408.465-77%
Eps---2836.409-2836.4090%-12.225-100%-955.301-66%-575.820-80%-411.756-85%
Ev To Ebitda Ratio--0.0790.0790%-0.820+1138%-0.504+737%-1.193+1610%-1.193+1610%
Free Cash Flow Per Share---3928.377-3928.3770%-7.931-100%-1316.890-66%-792.698-80%-566.395-86%
Free Cash Flow To Equity Per Share---1793.073-1793.0730%-7.931-100%-605.109-66%-357.142-80%-255.106-86%
Gross Profit Margin--1.0001.0000%696.240-100%232.747-100%140.048-99%100.320-99%
Intrinsic Value_10Y_max---41982.602----------
Intrinsic Value_10Y_min---57948.984----------
Intrinsic Value_1Y_max---1532.225----------
Intrinsic Value_1Y_min---2474.008----------
Intrinsic Value_3Y_max---6642.168----------
Intrinsic Value_3Y_min---10364.120----------
Intrinsic Value_5Y_max---14209.727----------
Intrinsic Value_5Y_min---21405.716----------
Market Cap13791.750-11622%1616673.1401616673.1400%397600.000+307%929036.047+74%1409776.628+15%1006983.306+61%
Net Profit Margin----0%-0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%-0%
Pb Ratio0.000+97%-0.002-0.0020%0.206-101%0.083-102%0.073-102%0.052-103%
Pe Ratio0.000+97%0.0000.0000%-0.026+19438%-0.021+15408%-0.083+61976%-0.059+44240%
Price Per Share0.011-3323%0.3800.3800%0.320+19%0.441-14%0.950-60%0.679-44%
Price To Free Cash Flow Ratio0.000+97%0.0000.0000%-0.040+41613%-0.028+28760%-0.075+77807%-0.054+55548%
Price To Total Gains Ratio0.000+97%-0.002-0.0020%-0.027+1446%-0.022+1150%0.009-119%0.009-119%
Quick Ratio--1.2251.2250%1.188+3%2.850-57%5.243-77%3.752-67%
Return On Assets---7.757-7.7570%-1.578-80%-3.475-55%-4.075-47%-19.537+152%
Return On Equity----0%-7.8530%-3.0490%-1.8940%-1.3530%
Total Gains Per Share---216.337-216.3370%-11.787-95%-81.650-62%-42.516-80%-30.683-86%
Usd Book Value---913760000.000-913760000.0000%1934321.000-47339%-298415540.000-67%-172395594.600-81%-123700424.571-86%
Usd Book Value Change Per Share---216.337-216.3370%-11.787-95%-81.650-62%-42.516-80%-30.683-86%
Usd Book Value Per Share---214.780-214.7800%1.557-13896%-66.627-69%-34.621-84%-25.078-88%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value---954700326.860-954700326.8600%1845088.000-51843%-312060569.953-67%-224291408.465-77%-224291408.465-77%
Usd Eps---2836.409-2836.4090%-12.225-100%-955.301-66%-575.820-80%-411.756-85%
Usd Free Cash Flow---16712900000.000-16712900000.0000%-9853772.000-100%-5580200160.000-67%-3351305586.400-80%-2394208486.000-86%
Usd Free Cash Flow Per Share---3928.377-3928.3770%-7.931-100%-1316.890-66%-792.698-80%-566.395-86%
Usd Free Cash Flow To Equity Per Share---1793.073-1793.0730%-7.931-100%-605.109-66%-357.142-80%-255.106-86%
Usd Market Cap13791.750-11622%1616673.1401616673.1400%397600.000+307%929036.047+74%1409776.628+15%1006983.306+61%
Usd Price Per Share0.011-3323%0.3800.3800%0.320+19%0.441-14%0.950-60%0.679-44%
Usd Profit---12067225000.000-12067225000.0000%-15189508.000-100%-4034623605.000-67%-2424101457.400-80%-1732368483.000-86%
Usd Revenue----0%-0%-0%-0%-0%
Usd Total Gains Per Share---216.337-216.3370%-11.787-95%-81.650-62%-42.516-80%-30.683-86%
 EOD+2 -6MRQTTM+0 -0YOY+8 -243Y+7 -255Y+7 -2510Y+8 -24

3.3 Fundamental Score

Let's check the fundamental score of Virpax Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-150.000
Price to Book Ratio (EOD)Between0-10.000
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.225
Current Ratio (MRQ)Greater than10.630
Debt to Asset Ratio (MRQ)Less than11.587
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-7.757
Total2/10 (20.0%)

3.4 Technical Score

Let's check the technical score of Virpax Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.011
Total0/1 (0.0%)

4. In-depth Analysis

4.1 About Virpax Pharmaceuticals Inc

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also include AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.

Fundamental data was last updated by Penke on 2025-08-17 11:22:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitย Virpax Pharmaceuticals Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareย Virpax Pharmaceuticals Inc to theย Biotechnology industry mean.
  • A Net Profit Margin of 0.0%ย means thatย $0.00 for each $1ย in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Virpax Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--91.7%+91.7%
TTM--160.2%+160.2%
YOY--209.8%+209.8%
3Y--278.1%+278.1%
5Y--362.4%+362.4%
10Y--517.9%+517.9%
4.3.1.2. Return on Assets

Shows howย efficientย Virpax Pharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthyย but always compareย Virpax Pharmaceuticals Inc to theย Biotechnology industry mean.
  • -775.7% Return on Assets means thatย Virpax Pharmaceuticals Inc generatedย $-7.76 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Virpax Pharmaceuticals Inc:

  • The MRQ is -775.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -775.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-775.7%TTM-775.7%0.0%
TTM-775.7%YOY-157.8%-618.0%
TTM-775.7%5Y-407.5%-368.2%
5Y-407.5%10Y-1,953.7%+1,546.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-775.7%-12.0%-763.7%
TTM-775.7%-11.9%-763.8%
YOY-157.8%-11.2%-146.6%
3Y-347.5%-11.9%-335.6%
5Y-407.5%-11.6%-395.9%
10Y-1,953.7%-13.6%-1,940.1%
4.3.1.3. Return on Equity

Shows how efficient Virpax Pharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareย Virpax Pharmaceuticals Inc to theย Biotechnology industry mean.
  • 0.0% Return on Equity means Virpax Pharmaceuticals Inc generated $0.00ย for eachย $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Virpax Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-785.3%+785.3%
TTM-5Y-189.4%+189.4%
5Y-189.4%10Y-135.3%-54.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--14.2%+14.2%
TTM--14.7%+14.7%
YOY-785.3%-15.0%-770.3%
3Y-304.9%-16.5%-288.4%
5Y-189.4%-17.0%-172.4%
10Y-135.3%-19.2%-116.1%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Virpax Pharmaceuticals Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measuresย how efficient Virpax Pharmaceuticals Inc is operatingย .

  • Measures how much profit Virpax Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareย Virpax Pharmaceuticals Inc to theย Biotechnology industry mean.
  • An Operating Margin of 0.0%ย means the company generated $0.00 ย for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Virpax Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--165.0%+165.0%
TTM--237.4%+237.4%
YOY--213.1%+213.1%
3Y--267.2%+267.2%
5Y--347.4%+347.4%
10Y--509.4%+509.4%
4.3.2.2. Operating Ratio

Measures how efficient Virpax Pharmaceuticals Inc is keepingย operating costsย low.

  • Below 1 is considered healthy (always compare toย Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Virpax Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.960-1.960
TTM-2.837-2.837
YOY-3.005-3.005
3Y-3.743-3.743
5Y-4.738-4.738
10Y-6.841-6.841
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Virpax Pharmaceuticals Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Virpax Pharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toย Biotechnology industry mean).
  • A Current Ratio of 0.63ย means the company has $0.63 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Virpax Pharmaceuticals Inc:

  • The MRQ is 0.630. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.630. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.630TTM0.6300.000
TTM0.630YOY1.251-0.621
TTM0.6305Y5.443-4.813
5Y5.44310Y3.897+1.546
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6303.467-2.837
TTM0.6303.689-3.059
YOY1.2514.099-2.848
3Y2.7464.658-1.912
5Y5.4435.739-0.296
10Y3.8976.151-2.254
4.4.3.2. Quick Ratio

Measures if Virpax Pharmaceuticals Inc is able to pay off Short-term Debt but only usingย theย most liquid assets.

  • Above 1 is considered healthy butย always compareย Virpax Pharmaceuticals Inc to theย Biotechnology industry mean.
  • A Quick Ratio of 1.22ย means the company can pay off $1.22 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Virpax Pharmaceuticals Inc:

  • The MRQ is 1.225. The company is just able to pay all its short-term debts with the most liquid assets.
  • The TTM is 1.225. The company is just able to pay all its short-term debts with the most liquid assets.
Trends
Current periodCompared to+/- 
MRQ1.225TTM1.2250.000
TTM1.225YOY1.188+0.037
TTM1.2255Y5.243-4.018
5Y5.24310Y3.752+1.490
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2252.994-1.769
TTM1.2253.326-2.101
YOY1.1883.908-2.720
3Y2.8504.438-1.588
5Y5.2435.809-0.566
10Y3.7526.537-2.785
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Virpax Pharmaceuticals Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %ย of Virpax Pharmaceuticals Incย assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareย Virpax Pharmaceuticals Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.59ย means that Virpax Pharmaceuticals Inc assets areย financed with 158.7% credit (debt) and the remaining percentage (100% - 158.7%)ย is financed by its owners/shareholders.ย 

Let's take a look of the Debt to Asset Ratio trends of Virpax Pharmaceuticals Inc:

  • The MRQ is 1.587. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 1.587. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ1.587TTM1.5870.000
TTM1.587YOY0.799+0.788
TTM1.5875Y2.531-0.944
5Y2.53110Y13.219-10.688
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5870.340+1.247
TTM1.5870.358+1.229
YOY0.7990.335+0.464
3Y0.8480.343+0.505
5Y2.5310.350+2.181
10Y13.2190.378+12.841
4.5.4.2. Debt to Equity Ratio

Measures ifย Virpax Pharmaceuticals Inc is able toย pay off its debts by usingย shareholders equity.

  • Below 2 is considered healthy butย always compareย Virpax Pharmaceuticals Inc to theย Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Virpax Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY3.978-3.978
TTM-5Y0.844-0.844
5Y0.84410Y0.603+0.241
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.394-0.394
TTM-0.440-0.440
YOY3.9780.436+3.542
3Y1.3880.462+0.926
5Y0.8440.468+0.376
10Y0.6030.518+0.085
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measuresย how much money you payย for each share forย every $1 in earnings Virpax Pharmaceuticals Inc generates.

  • Above 15 is considered overpriced butย always compareย Virpax Pharmaceuticals Inc to theย Biotechnology industry mean.
  • A PE ratio of 0.00 means the investor is paying $0.00ย for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Virpax Pharmaceuticals Inc:

  • The EOD is 0.000. Based on the earnings, the company is expensive. -2
  • The MRQ is 0.000. Based on the earnings, the company is expensive. -2
  • The TTM is 0.000. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD0.000MRQ0.000+0.000
MRQ0.000TTM0.0000.000
TTM0.000YOY-0.026+0.026
TTM0.0005Y-0.083+0.083
5Y-0.08310Y-0.059-0.024
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.000-2.560+2.560
MRQ0.000-2.297+2.297
TTM0.000-2.662+2.662
YOY-0.026-3.749+3.723
3Y-0.021-3.773+3.752
5Y-0.083-6.353+6.270
10Y-0.059-7.043+6.984
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Virpax Pharmaceuticals Inc:

  • The EOD is 0.000. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is 0.000. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 0.000. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD0.000MRQ0.000+0.000
MRQ0.000TTM0.0000.000
TTM0.000YOY-0.040+0.040
TTM0.0005Y-0.075+0.075
5Y-0.07510Y-0.054-0.022
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.000-3.491+3.491
MRQ0.000-3.099+3.099
TTM0.000-3.812+3.812
YOY-0.040-4.274+4.234
3Y-0.028-5.149+5.121
5Y-0.075-8.383+8.308
10Y-0.054-9.373+9.319
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofย Virpax Pharmaceuticals Inc is to cheap or to expensiveย compared to its book value.

  • At or below 1 is considered healthyย (always compare to Biotechnology industry mean).
  • A PB ratio of 0.00 means the investor is paying $0.00ย for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Virpax Pharmaceuticals Inc:

  • The EOD is 0.000. Based on the equity, the company is expensive. -2
  • The MRQ is -0.002. Based on the equity, the company is expensive. -2
  • The TTM is -0.002. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD0.000MRQ-0.002+0.002
MRQ-0.002TTM-0.0020.000
TTM-0.002YOY0.206-0.207
TTM-0.0025Y0.073-0.075
5Y0.07310Y0.052+0.021
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.0002.315-2.315
MRQ-0.0022.006-2.008
TTM-0.0022.209-2.211
YOY0.2062.431-2.225
3Y0.0832.578-2.495
5Y0.0733.708-3.635
10Y0.0524.430-4.378
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Virpax Pharmaceuticals Inc.

4.8.1. Institutions holding Virpax Pharmaceuticals Inc

Institutions are holding 0.019% of the shares of Virpax Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-12-31Geode Capital Management, LLC0.13110418991392849.7944
2024-12-31HRT FINANCIAL LLC0.07940.000125368253680
2024-12-31Virtu Financial LLC0.0740.000523657236570
2024-12-31UBS Group AG0.041013100-7335-35.8943
2024-12-31XTX Topco Ltd0.04040.000412905129050
2024-12-31Tower Research Capital LLC0.02430.000177543917102.085
2024-12-31Morgan Stanley - Brokerage Accounts0.001604994843226.6667
2025-03-31SBI Securities Co Ltd0.0084010884350
2024-12-31Bank of America Corp0.00020652875.6757
2024-12-31Hantz Financial Services, INC.001000
2024-12-31Citadel Advisors Llc000-31382-100
2024-12-31Signature Resources Capital Management, LLC000-50-100
2024-12-31TWO SIGMA SECURITIES, LLC000-12522-100
Total 0.40040.0011125365+29082+23.2%

4.9.2. Funds holding Virpax Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31Fidelity Extended Market Index0.07920101200
2025-03-31Fidelity Series Total Market Index0.0393050322983.5766
2025-03-31Fidelity Total Market Index0.0274035000
2025-03-31Vanguard Institutional Extnd Mkt Idx Tr0.0207026500
2024-12-31NT Ext Eq Mkt Indx Fd DC Lend T40.000401371370
2024-12-31NT Ext Eq Mkt Indx Fd DC Lend T30.000401371370
2025-03-31NT Ext Equity Mkt Idx Fd - NL0.00303800
2025-03-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.0023030-1-3.2258
2025-03-31Northern Trust Extended Eq Market Idx0.001802300
2025-03-31NT Ext Equity Mkt Idx Fd - L0.001802300
2025-03-31Spartan Total Market Index Pool E0.0009012-1-7.6923
2025-03-31NT Ext Eq Mkt Indx Fd DC Lending Tier 50.00050600
2025-03-31SSgA U.S. Total Market Index Strategy0.00010100
Total 0.177802537+501+19.7%

5.3. Insider Transactions

Insiders are holding 0.001% of the shares of Virpax Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2022-05-24Jerrold SendrowBUY18322.5
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets1,555,614
Total Liabilities2,469,374
Total Stockholder Equity-913,760
 As reported
Total Liabilities 2,469,374
Total Stockholder Equity+ -913,760
Total Assets = 1,555,614

Assets

Total Assets1,555,614
Total Current Assets1,555,614
Long-term Assets0
Total Current Assets
Cash And Cash Equivalents 1,513
Short-term Investments 1,511,544
Other Current Assets 42,557
Total Current Assets  (as reported)1,555,614
Total Current Assets  (calculated)1,555,614
+/-0
Long-term Assets
Long-term Assets  (as reported)0
Long-term Assets  (calculated)0
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities2,469,374
Long-term Liabilities0
Total Stockholder Equity-913,760
Total Current Liabilities
Other Current Liabilities 2,469,374
Total Current Liabilities  (as reported)2,469,374
Total Current Liabilities  (calculated)2,469,374
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock0
Retained Earnings -71,611,360
Other Stockholders Equity 70,697,600
Total Stockholder Equity (as reported)-913,760
Total Stockholder Equity (calculated)-913,760
+/-0
Other
Capital Stock0
Cash and Short Term Investments 1,513,057
Common Stock Shares Outstanding 4,254
Liabilities and Stockholders Equity 1,555,614
Net Debt -1,513
Net Invested Capital -914
Net Working Capital -914



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
> Total Assets 
62
47
465
39,572
19,674
9,628
1,555,614
1,555,6149,62819,67439,5724654762
   > Total Current Assets 
62
47
73
39,572
19,674
9,628
1,555,614
1,555,6149,62819,67439,572734762
       Cash And Cash Equivalents 
48
42
55
36,842
18,995
9,142
1,513
1,5139,14218,99536,842554248
       Short-term Investments 
0
0
0
0
0
0
1,511,544
1,511,544000000
       Net Receivables 
0
1
0
0
0
0
0
0000010
       Other Current Assets 
13
4
18
2,730
678
487
42,557
42,5574876782,73018413
   > Long-term Assets 
0
0
392
0
0
0
0
000039200
> Total Liabilities 
1,254
2,779
4,682
2,088
3,095
7,694
2,469,374
2,469,3747,6943,0952,0884,6822,7791,254
   > Total Current Liabilities 
1,254
2,779
3,660
2,088
3,095
7,694
2,469,374
2,469,3747,6943,0952,0883,6602,7791,254
       Short-term Debt 
500
1,265
544
0
0
0
0
00005441,265500
       Short Long Term Debt 
500
1,265
544
0
0
0
0
00005441,265500
       Accounts payable 
7
3
22
20
38
0
0
0038202237
       Other Current Liabilities 
740
1,497
3,080
2,060
3,057
7,694
2,469,374
2,469,3747,6943,0572,0603,0801,497740
   > Long-term Liabilities 
500
1,265
1,022
0
1
0
0
00101,0221,265500
       Deferred Long Term Liability 
0
0
392
0
0
0
0
000039200
> Total Stockholder Equity
-1,193
-2,732
-4,216
37,485
16,579
1,934
-913,760
-913,7601,93416,57937,485-4,216-2,732-1,193
   Common Stock
0
0
0
0
0
0
0
0000000
   Retained Earnings -71,611,360-59,544-44,355-22,704-10,648-6,308-3,002
   Capital Surplus 0000000
   Treasury Stock0000000
   Other Stockholders Equity 
1,809
3,576
6,432
60,189
60,934
61,478
70,697,600
70,697,60061,47860,93460,1896,4323,5761,809



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-0
Gross Profit00
 
Operating Income (+$)
Gross Profit0
Operating Expense-12,079,935
Operating Income-12,079,935-12,079,935
 
Operating Expense (+$)
Research Development5,819,308
Selling General Administrative6,260,627
Selling And Marketing Expenses0
Operating Expense12,079,93512,079,935
 
Net Interest Income (+$)
Interest Income0
Interest Expense-103,750
Other Finance Cost-103,646
Net Interest Income-104
 
Pretax Income (+$)
Operating Income-12,079,935
Net Interest Income-104
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-12,067,225-12,092,645
EBIT - interestExpense = -12,274,725
-12,067,225
-11,963,475
Interest Expense103,750
Earnings Before Interest and Taxes (EBIT)-12,170,975-11,963,475
Earnings Before Interest and Taxes (EBITDA)-12,079,935
 
After tax Income (+$)
Income Before Tax-12,067,225
Tax Provision-0
Net Income From Continuing Ops-12,067-12,067,225
Net Income-12,067,225
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses15,690
Total Other Income/Expenses Net12,710104
 

Technical Analysis of Virpax Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Virpax Pharmaceuticals Inc. The general trend of Virpax Pharmaceuticals Inc is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Virpax Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Virpax Pharmaceuticals Inc Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Supportย is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistanceย is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Virpax Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 0.012 < 0.14 < 0.209.

The bearish price targets are: 0.011 > 0.011 > 0.011.

Know someone who trades $VRPX? Share this with them.๐Ÿ‘‡

Virpax Pharmaceuticals Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theย moving averageย of the selected period.

  • Moving averages are laggingย trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Virpax Pharmaceuticals Inc. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Virpax Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theย momentumย of theย selected period based on two moving averages.

  • MACD is aย lagging momentumย indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Virpax Pharmaceuticals Inc.

Virpax Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartVirpax Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Virpax Pharmaceuticals Inc. The current adx is .

Virpax Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Showsย the current trend.
  • Showsย potential entry signals.
  • Showsย ย potential exit signals.
  • Can be used to placeย trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Virpax Pharmaceuticals Inc.

Virpax Pharmaceuticals Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumย indicator, meaning the signals are instant.
  • Rangesย between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Virpax Pharmaceuticals Inc.

Virpax Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartVirpax Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Comparesย a certain price to multiple prices ranging over time.

  • Leadingย momentumย indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Rangesย between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Virpax Pharmaceuticals Inc.

Virpax Pharmaceuticals Inc Daily Stochastic Oscillator ChartVirpax Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,ย the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Virpax Pharmaceuticals Inc.

Virpax Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartVirpax Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Virpax Pharmaceuticals Inc.

Virpax Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartVirpax Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

ย Shows the current price relative to the highest high over the last 14 days.
ย 

  • Lagging momentum indicator
  • Ranging between 0 andย -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Virpax Pharmaceuticals Inc.

Virpax Pharmaceuticals Inc Daily Williams %R ChartVirpax Pharmaceuticals Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldย 

Score

Let's take a look at the Bollinger Bands of Virpax Pharmaceuticals Inc.

Virpax Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Virpax Pharmaceuticals Inc.

Virpax Pharmaceuticals Inc Daily Average True Range (ATR) ChartVirpax Pharmaceuticals Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

ย Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Virpax Pharmaceuticals Inc.

Virpax Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartVirpax Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Virpax Pharmaceuticals Inc.

Virpax Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartVirpax Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Virpax Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-22STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-24MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-29WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-08WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-13STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-14STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-16STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-19STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-22STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-29STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-03RSI LONG ENTRY SHORT CLOSE30 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-04STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-06STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-09STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-10STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-11CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-16STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-17CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-18BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-06-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-23STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-24SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-25STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-02CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-07-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-09CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-16CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-07-17WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-18STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-21CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-25STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-28RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-07-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-06MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-08-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-08-14MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-08-15MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-08-18WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-08-22MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-08-25STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-09-04RSI LONG ENTRY SHORT CLOSE30 crossover to upside
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.

6.3. Candlestick Patterns

Virpax Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Virpax Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.011
Total0/1 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Virpax Pharmaceuticals Inc with someone you think should read this too:
  • Are you bullish or bearish on Virpax Pharmaceuticals Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Virpax Pharmaceuticals Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Virpax Pharmaceuticals Inc

I send you an email if I find something interesting about Virpax Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Virpax Pharmaceuticals Inc.

Receive notifications about Virpax Pharmaceuticals Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.